Are these changes related to a clinical parameter? (efficacy of a new therapy, monitoring of the immune response to a vaccine, emergence of the resistance phenomenon in precision medicine, etc.)

Can sub-populations of patients responding be determined? (translational biomarker)

We can support you with designing and implementing the radionuclide labeling of your chemical or biological molecules of interest. Our radiochemical labs have secured handling permits for all the isotopes used in imaging and nuclear therapeutics, and they are able to produce batches for preclinical and clinical use.

Pharmimage handles the translation between the preclinical and clinical phases, including at the Georges François Leclerc cancer research center and Dijon CHU university hospital.